The Tube vs Trabeculectomy Trial (TVT) found that the 350-mm 2 Baerveldt implant (tube) and trabeculectomy with mitomycin may be similarly effective in lowering intraocular pressure in primary open-angle glaucoma. However, to date, there are no published long-term clinical data on the cost-effectiveness of trabeculectomy with mitomycin vs tube insertion.
curs when medical and laser therapy have failed to control intraocular pressure (IOP). The criterion standard incisional surgical procedure for glaucoma has traditionally been trabeculectomy. However, in response to growing concerns over bleb-related complications and relative lack of predictability, tube insertion operations have been increasing in popularity. 2, 3 Clinical trial data supported the growing preference for tubes when the Tube Versus Trabeculectomy trial (TVT) 4 reported similar IOP reduction between the 2 arms. To our knowledge, there are no published long-term clinical data on the cost-effectiveness of trabeculectomy with mitomycin vs the 350-mm 2 Baerveldt implant (tube). The purpose of this study was to estimate the mean relative costs and quality of life for each surgical intervention compared with maximal medical treatment using decision analysis modeling. To do this, we created a mathematical Markov model that incorporated clinical trial data on rates of surgical success, risks of short-and long-term surgical complications, need for supplemental medication, rates of visual progression, associated medical and surgical costs, and quality of life based on visual preservation and adverse effects of surgical intervention. We have previously used similar methods to assess the effect on visual function of community glaucoma screening using spectral-domain optical coherence tomography. 5 A Markov model is a computer-based algorithm that assigns each simulated patient to one of a finite number of discrete health states for a period called a cycle. At the end of each cycle, patients may remain in their health state or progress to a different health state based on probabilities that are specified for transitioning from one health state to another. All probabilities, health states, and outcomes were derived from peerreviewed clinical trial data. The primary outcomes of our Markov model were patient utility and cost-effectiveness for each of the surgical interventions.
Methods

Decision Analytic Model
We simulated the course of 100 000 hypothetical patients with primary open-angle glaucoma treated with surgery or maximal medical treatment. The project was exempt from institutional review board approval because it did not involve human subjects, and all data were obtained from the published literature. The baseline visual field mean deviation for each simulated patient with glaucoma was randomly selected from a probability distribution function and was tracked for every year that a patient survived during the 5-year time horizon. In the first year after surgery, patients were subject to (1) the risk of early complications, (2) early failure with or without resultant visual field progression, (3) visual field progression despite surgical success, and (4) death. In subsequent years, patients were subject to (1) the risk of late complications, (2) late failure with or without resultant visual field progression, (3) visual field progression despite surgical success, and (4) death. Surgical success and visual field progression were not mutually exclusive events, although the rates of visual field progression in the surgical success states were lower than in the surgical failure states. The medical arm was subject to death and the risk of visual field progression despite maximal tolerated medical treatment.
In total, the Markov model included 10 possible health states derived from surgical status, central visual acuity, and visual field stage as defined by the Bascom Palmer glaucoma staging system; only visual acuity and visual field states applied to the medication arm ( Figure 1) . The model was programmed with TreeAge Pro 2012 statistical software (TreeAge Software Inc).
Population
The simulated cohort had a mean age of 78 years, which reflected the mean age of patients undergoing glaucoma surgery. 6, 7 Age-specific mortality rates for individuals were based on US Census data.
Probability of Surgical Success
The model was calibrated to match the early and late failure rates of the trabeculectomy and tube groups presented by Gedde et al 4, 8 in the TVT. Failure in our model was defined as an IOP greater than 21 mm Hg with less than 20% reduction from baseline on 2 consecutive visits as defined by the TVT. Early failure rates were derived from 1-year results of the TVT. To calculate the late annual failure rates, the overall failure rates between follow-up years 1 and 5 of the TVT were annualized by converting the 4-year probability to instantaneous rates from which 1-year probabilities were derived using the following equation: r = −[ln (1 -p)]/t, where p indicates 1 -exp {-rt}; r, rate; and t, time. Patients in whom surgical intervention failed were assumed to resume maximal medical 
Probability of Early and Late Surgical Complications
Complications were selected only if their occurrence could result in potential visual loss or need for additional operation because of the complication itself or subsequent failure of the initial glaucoma surgery. The model included 5 early complications for the trabeculectomy group: endophthalmitis, suprachoroidal hemorrhage, bleb leak that required revision, hypotony maculopathy, or corneal edema that required penetrating keratoplasty. Likewise, the model included 5 early complications for the tube group: endophthalmitis, suprachoroidal hemorrhage, tube erosion, corneal edema that required penetrating keratoplasty, or diplopia. Probabilities for all early surgical complications were based on the 1-year results of the TVT 9-11 ( Table 1 ). All late complications were derived from the 5-year TVT results. Like late failure, annual results were obtained by converting the 5-year complication probability to an instantaneous rate, which was then reconverted to an annual probability. Management of complications and visual recuperation were derived from peerreviewed publications, which is detailed in the eMethods in the Supplement.
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Estimating Baseline Visual Field Loss and Rates of Progression
The baseline magnitude of an individual's visual field damage was selected from a probability distribution function that was intended to reflect a cohort of potential surgical patients (Table 1) . Progression was defined as a decrease of 3 dB of mean deviation of visual field loss. Annual field progression in the medical treatment arm was calculated by using the rates of progression from 2 peer-reviewed studies 16, 18 of eyes that required surgery but continued to receive medical treatment.
Rates of progression in the surgical success arm were estimated to be 10% as derived from the work of Folgar and colleagues. 16 Because no current studies have compared rates of visual field progression between eyes with successful and failed glaucoma incisional operations, visual field data were extrapolated from the work of Folgar et al and crossvalidated with the visual field data from the Collaborative Ini- 17 In both studies, patients with failed surgery had a 1.50 relative risk of progression relative to patients with successful glaucoma surgery; of note, the differences in the study populations were not statistically significant (P = .10 for the Collaborative Initial Glaucoma Treatment Study and P = .22 for the study derived from the work of Folgar et al) (eMethods in the Supplement).
Estimating Medication for IOP
The mean annual number of supplemental medications was derived from the 5-year TVT data. 4 Surgical failures were assigned the cost of maximal tolerated medical treatment, which was defined as all 4 medications (β-blocker, carbonic anhydrase inhibitor, α-adrenergic agonist, and prostaglandin).
Costs
The costs, in 2013 US dollars, of surgical and medical management were derived from the 2013 national Medicare reimbursement rates for Current Procedural Terminology codes and the Ambulatory Payment Classification reimbursement codes (services) as documented by the American Medical Association (code source). Medication costs were obtained from the 2013 Red Book using the lowest current price available ( Table 2) . Future costs were converted to net present values using a discount rate of 3% annually. The costs of initial surgery included physician and hospital outpatient reimbursement rates, including surgical costs and anesthesia, direct costs of medical management in the postoperative period, costs of medical and surgical management of adverse events, costs of supplemental IOP-lowering medications, routine glaucoma follow-up, and lost wages. Follow-up costs were derived from the preferred practice patterns and included office visits and ancillary testing. Patients with failed operations and patients with progressive disease received additional office visits with ancillary testing. Blind patients incurred costs associated with low vision aids (eMethods in the Supplement).
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Outcomes Quality-adjusted life-years (QALYs) are a frequent measure of utility in decision analysis and cost-effectiveness modeling. The QALYs reflect a range from death to perfect health, anchored at 0 to 1, respectively, for each year of life. Utilities for visual field loss and blindness are listed in Table 1. 12,14,15 In our model, the patient was assigned to the lowest utility associated with his/her ophthalmic health state. For example, one cycle in the health state, "surgical success with advanced visual field loss and moderate central visual acuity," could be associated with 0.86 QALYs for the visual field or 0.74 QALYs for the visual acuity. Because the model assigned the lower utility, the patient gained 0.74 QALYs for that cycle. In an attempt to reflect the disutility associated with additional medical treatment 30,31 and the psychological discomfort (eg, anxiety) of having had failed surgery, QALYs were reduced 10% for patients in whom surgery failed. This approach is consistent with previous ophthalmic models that have incorporated a decreased utility in patients with adverse events after surgical procedures.
Sensitivity Analyses
Sensitivity analyses were performed to evaluate whether the uncertainty of our parameters would result in a change of projected outcome (eMethods in the Supplement). For the purposes of our deterministic sensitivity analysis, we calculated a weighted mean 1-year success rate for each of the 2 surgical angle glaucoma. In addition, we conducted a probabilistic sensitivity analysis using Monte Carlo simulation of input parameters simultaneously (eTable 2 in the Supplement). Parameters were varied using β-distributions except for age, which had a normal distribution. For all sensitivity analyses, we used a willingnessto-pay (WTP) threshold of $50 000 per QALY to determine which intervention was best because parameters were varied. The WTP represents the amount of additional cost that the paying party (eg, government, patient, or society) is willing to pay for one QALY added.
Results
Model Validation
Our model predicted a 4-year surgical failure rate of 34%, whereas Jampel et al 43 reported a failure rate of 30% in a 4-year case series of almost 800 patients. The predicted probabilities of bleb leak and tube erosion were in keeping with reported rates from the peer-reviewed literature: 4% vs predicted 3% for bleb leak 43 and 1% vs predicted 1% for tube erosion.
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Base Case
During a 5-year time horizon, the mean cost of medical treatment only was $6172, the mean cost of a trabeculectomy was $7872, and the mean cost of a tube insertion was $10 075, resulting in a difference of $1700 (95% CI, $1644-$1770) between medical treatment and trabeculectomy, $3904 (95% CI, $3858-$3953) between medical treatment and tube insertion, and $2203 (95% CI, $2121-$2261) between trabeculectomy and tube insertion. The mean 5-year probability of blindness (defined as visual field mean deviation <−23) was 4% for both surgical procedures and 15% for medical treatment. After 5 years, the mean patient-related utility gained was 3.10 QALYs after medical treatment, 3.30 QALYs after a trabeculectomy, and 3.38 QALYs after tube insertion. The incremental cost-effectiveness ratio (ICER), calculated as the additional cost per QALY gained, was $8289 per QALY for trabeculectomy relative to medical treatment, $13 896 per QALY for tube insertion relative to medical treatment, and $29 055 per QALY for tube insertion relative to trabeculectomy (eFigure 1 in the Supplement).
Sensitivity Analysis
A sensitivity analysis was performed to evaluate the effect of parameter uncertainties on the outcomes of the model ( Table 3) . When the rate of early failure in the trabeculectomy group was decreased to the 7.5% meta-analysis rate, the cost of trabeculectomy relative to medical treatment decreased to $6401 per QALY, and the cost of tube insertion relative to trabeculectomy increased to $40 891 per QALY. Likewise, when the tube early failure rate was increased to the calculated metaanalysis rate of 7.2%, the cost of tube insertion relative to medical treatment increased to $14 302 per QALY, and the cost of tube insertion relative to trabeculectomy increased to $31 653 per QALY. When both failure rates are incorporated into the model, the incremental cost per QALY of tube insertion relative to trabeculectomy increases to $55 223 per QALY, and tube insertion is no longer a cost-effective option when assuming a WTP of $50 000. Because the tube was most costly, we assessed the effect of varying the trabeculectomy failure rate until the cost of a tube insertion and a trabeculectomy were equal. The increased trabeculectomy failure rate would result in both additional use of medication and a higher risk of progression, resulting in increased associated costs. If all other parameters were held constant, the risk of early trabeculectomy failure would need to be 64% for the cost of a tube insertion and a trabeculectomy to be equal during a 5-year period.
We then simultaneously varied the 1-year failure rates of tube and trabeculectomy in a 2-way sensitivity analysis to determine when the trabeculectomy would become the preferred treatment option in terms of cost-effectiveness per QALY. Trabeculectomy became the preferred option when the 1-year trabeculectomy failure probability decreased to approximately 0.08 and the tube insertion 1-year failure rate increased to approximately 0.045. In this case, trabeculectomy would have an incremental gain of 0.01 QALYs, and tube insertion would have a loss of 0.02 QALYs, resulting in an ICER of $50 828 per QALY. Under this scenario and given a WTP of $50 000 per QALY, the trabeculectomy would become the favored treatment choice (eFigure 2 in the Supplement).
Several additional parameters, including rate of progression in patients with and without surgical success, additional operation after failed surgery, time horizon, QALY values, incidence of adverse events, decrease in Medicare reimbursement for tube insertion, and medical treatment costs were varied but had no significant effect on costs or utilities of either surgery (eResults in the Supplement provide the complete results of sensitivity analyses).
Probalistic Sensitivity Analysis
We varied all parameters in the interventions simultaneously to test the stability of the model (eTable 2 in the Supplement). The results of this probalistic sensitivity analysis are depicted in a cost-effectiveness acceptability curve comparing the 2 surgical procedures to medication alone ( Figure 2) . Trabeculectomy was more likely to be the preferred strategy at lower WTP values. Medical treatment was the preferred treatment in 100% of simulations at a WTP of $0 per QALY and 1% at $15 000 per QALY but 0% at higher WTP thresholds. Trabeculectomy was preferred in 99% of simulations at $15 000 per QALY, 33% at $45 000 per QALY, 14% at $60 000 per QALY, and 4% at $90 000 per QALY. Likewise, tube insertion was preferred in 67% at $45 000 per QALY, 86% at $60 000 per QALY, and 97% at $105 000 per QALY.
Discussion
The increasing popularity of tube insertions has been validated by the TVT study in terms of efficacy and complication rates. To date, no cost-effectiveness studies have compared the 2 surgical procedures with medical treatment. The intent of this study was to evaluate whether the more expensive surgical options were cost-effective. We found that the tube was more expensive and provided marginally higher utility than trabeculectomy at 5 years. When compared with medication alone, both operations were highly cost-effective.
There are at least 6 limitations of this study. First, in developing the model, several assumptions had to be made because of the relative paucity of sufficient data. Among these assumptions were (1) populating the model with early and late tube failure rates derived exclusively from the TVT studies, (2) assuming that patients in whom surgery failed later received maximum medical treatment, and (3) calibrating the model to match the relative rates of visual field progression using data that were largely derived from a single retrospective cohort study. To test these assumptions, we performed multiple sensitivity analyses but found no significant effect on costs or utilities of either surgery.
Second, our primary effectiveness outcome was quality of life. Although QALYs are a common measure of health-related utility, some experts argue that the concept of a QALY fails to accurately capture patients' actual perceptions and preferences. 45 In glaucoma research, the inherent weaknesses of the QALY as a utility measure are compounded by limited data and varying assignment of QALYs when different methodologic approaches are applied 46 (the eDiscussion in the Supplement provides further discussion of QALY and WTP). Third, additional surgical selection factors were not considered in this model. Factors such as preservation of conjunctiva for future operations, viability of conjunctiva, ophthalmic surgical history, patient adherence, and patient preference are all unaccounted for in this model.
Fourth, because the TVT study did not exclude patients with prior ophthalmic surgery, which is a known risk factor for glaucoma surgical failure, 47 our model may have had an increased surgical failure rate relative to eyes that were not operated on. However, because this would be true in both surgical groups, the effects should be nondifferential and should not affect the relative cost or benefit between the 2 operations. This limitation would, however, decrease the efficacy of both operations relative to medications and would increase the ICERs of either surgery relative to medication.
Fifth, not all complications included in the TVT study were included in the model. We decided instead to include the most serious complications of surgery. Nevertheless, additional outliers may exist.
Sixth, this study primarily used data from the TVT, and therefore generalization should be done judiciously. In particular, these data may not be applicable to eyes without previous surgery. In addition, there may be differences from other implants, such as Molteno and Ahmed, or trabeculectomy with fluorouracil or without antimetabolite.
Conclusions
The results of this study suggest that tube insertion and trabeculectomy with mitomycin are cost-effective procedures. Quality of life and 5-year cost burden are markedly similar for tube insertion and trabeculectomy compared with medical treatment. When compared with each other, trabeculectomy had a substantially lower cost per QALY than tube insertion. In our model, tube insertion became relatively more costeffective when rates of visual field progression after surgical failure were increased, and trabeculectomy likewise became more cost-effective when trabeculectomy failure rates were decreased from rates derived from the TVT to our calculated meta-analysis rate. Future studies should focus on rates of visual field progression after both surgical procedures.
